YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
The available CDE acceptance records list 27 drug applications between 5 August 2023 and 11 August 2023 (data as of 13 November 2026 06:00). Of these, generic applications numbered 4, covering 3 drug names.
2023/08/05 – 2023/08/11
- New acceptances this week
- 27
- Drugs with new generic filings (by drug name, de-duplicated)
- 3
- Accepted this week, now under review
- 0
DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.
Names with a public page are linked.
New acceptances this week
By application type and drug type
27filings, 4 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 18 |
| Generic | 4 |
| Unspecified | 2 |
| Import re-registration | 2 |
| New drug | 1 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 11 |
| TCM | 8 |
| Therapeutic biologic | 7 |
| Biologic | 1 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
3 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | Esomeprazole Sodium for Injection | 2 | 1 | 1 |
| 2 | Peramivir Injection | 1 | 1 | 7 |
| 3 | Salbutamol Sulfate injection | 1 | 1 | 1 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
21 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | Shenyang Qing Gong Pharma Group Co., Ltd. romanized | 3 | 3 | 0 |
| 2 | Guangzhou Bai Ji Shen Zhou Biopharmaceutical Co., Ltd. romanized | 2 | 2 | 0 |
| 3 | PIERRE FABRE MEDICAMENT | 2 | 1 | 0 |
| 4 | You Shi Bi (Zhuhai) Pharmaceutical Co., Ltd. romanized | 2 | 1 | 0 |
| 5 | Hainan Huluwa Pharmaceutical Group Co., Ltd. | 2 | 1 | 2 |
| 6 | Amgen Inc. | 1 | 1 | 0 |
| 7 | Eli Lilly and Company | 1 | 1 | 0 |
| 8 | Novartis Pharma AG | 1 | 1 | 0 |
| 9 | Octapharma Produktionsgesellschaft Deutschland mbH | 1 | 1 | 0 |
| 10 | Pharmaceutical and Medical Device Regulatory Science Society of Japan | 1 | 1 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Compared across this platform's snapshots of the under-review list
Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.
DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers whose last snapshot sighting falls in this week and that this snapshot no longer lists; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
3 this week
| Accepted | Drug | Applicants |
|---|---|---|
| 2023/08/11Generic · Class 3 | Peramivir InjectionCYHS2302082 | Shaanxi Bo Sen Biopharmaceutical Shareholding Group Co., Ltd. romanized |
| 2023/08/10Generic · Class 3 | Salbutamol Sulfate injectionCYHS2302079 | Sichuan Guo Rui Pharma Co., Ltd. romanized |
| 2023/08/10New drug · Class 1 | M108单抗注射液 · No verified English nameCXSL2300537 | Ming Ji Biopharmaceutical (Beijing) Co., Ltd. romanized |
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.